应用早期18F-FDG PET/CT显像预测晚期黑色素瘤患者对免疫检查点抑制剂治疗的应答
这项前瞻性研究纳入20例接受免疫检查点抑制剂(ICI)治疗的晚期黑色素瘤患者,在治疗前、第21–28天(SCAN-2)及4个月时行18F-FDG PET/CT,评估各标准预测≥4个月最佳总体应答(BOR)的效能。SCAN-2时RECIST 1.1、免疫相关应答标准、PERCIST和EORTC标准的准确率分别为75%、70%、70%和65%;联合解剖与功能影像参数预测最终应答的敏感度100%、特异度93%、准确率95%。
要点
- SCAN-2时RECIST 1.1预测≥4个月BOR的准确率为75%,免疫相关应答标准为70%,PERCIST为70%,EORTC为65%。
- SCAN-2时预测BOR的最佳PERCIST阈值为>15.5%,最佳EORTC阈值为>14.7%。
- 联合SCAN-2解剖与功能影像数据预测最终应答:敏感度100%、特异度93%、准确率95%。
核心结论
- 在ICI治疗早期进行的18F-FDG PET/CT扫描中,联合功能与解剖影像参数似乎可预测晚期黑色素瘤患者的最终应答。
- 这些发现需要在更大队列中验证。
研究设计与样本
- 前瞻性研究,纳入20例接受ICI治疗的晚期黑色素瘤患者,于2012年4月至2013年12月入组。
- 在治疗开始前(SCAN-1)、第21–28天(SCAN-2)和4个月(SCAN-3)三个时间点行18F-FDG PET/CT。
- 按RECIST 1.1、免疫相关应答标准、PERCIST(PERCIST 1.0)和EORTC标准评估各治疗后时间点的肿瘤应答。
- 评估各指标预测≥4个月最佳总体应答(BOR)的效能特征。
主要发现
- 20例可评估患者接受ipilimumab(n=16)、BMS-936559(n=3)或nivolumab(n=1)治疗。
- ≥4个月BOR包括完全缓解(n=2)、部分缓解(n=2)、疾病稳定(n=1)和疾病进展(n=15)。
- SCAN-2时RECIST 1.1、免疫相关应答标准、PERCIST和EORTC标准预测≥4个月BOR的准确率分别为75%、70%、70%和65%。
- SCAN-2时预测BOR的最佳PERCIST和EORTC阈值分别为>15.5%和>14.7%。
- 联合SCAN-2采集的解剖与功能影像数据所建标准预测最终ICI应答的敏感度为100%、特异度为93%、准确率为95%。
关键数值与推荐
- SCAN-2时RECIST 1.1预测≥4个月BOR准确率75%。
- SCAN-2时免疫相关应答标准预测≥4个月BOR准确率70%。
- SCAN-2时PERCIST预测≥4个月BOR准确率70%,最佳阈值为>15.5%。
- SCAN-2时EORTC标准预测≥4个月BOR准确率65%,最佳阈值为>14.7%。
- 联合SCAN-2解剖与功能影像参数预测最终应答:敏感度100%、特异度93%、准确率95%。
临床怎么用
- 原文结论认为,ICI治疗早期18F-FDG PET/CT的功能与解剖影像参数联合似乎可预测晚期黑色素瘤患者的最终应答。
- 原文指出这些发现需要在更大队列中验证。
局限性
- 原文结论指出这些发现需要在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor of response to immune checkpoint inhibitors (ICIs) in patients with advanced melanoma. Methods: Twenty patients with advanced melanoma receiving ICI prospectively underwent 18F-FDG PET/CT at 3 scan intervals: before treatment initiation (SCAN-1), at days 21-28 (SCAN-2), and at 4 mo (SCAN-3). This study was approved by the institutional review board, and informed consent was received from all patients who were enrolled between April 2012 and December 2013. Tumor response at each posttreatment time point was assessed according to RECIST 1.1, immune-related response criteria, PERCIST (PERCIST 1.0), and European Organization for Research and Treatment of Cancer (EORTC) criteria. Performance characteristics of each metric to predict best overall response (BOR) at ≥ 4 mo were assessed. Results: Twenty evaluable patients were treated with ipilimumab (n = 16), BMS-936559 (n = 3), or nivolumab (n = 1). BOR at ≥ 4 mo included complete response (n = 2), partial response (n = 2), stable disease (n = 1), and progressive disease (n = 15). Response evaluations at SCAN-2 using RECIST 1.1, immune-related response criteria, PERCIST, and EORTC criteria demonstrated accuracies of 75%, 70%, 70%, and 65%, respectively, to predict BOR at ≥ 4 mo. Interestingly, the optimal PERCIST and EORTC threshold values at SCAN-2 to predict BOR were >15.5% and >14.7%, respectively. By combining anatomic and functional imaging data collected at SCAN-2, we developed criteria to predict eventual response to ICI with 100% sensitivity, 93% specificity, and 95% accuracy. Conclusion: Combining functional and anatomic imaging parameters from 18F-FDG PET/CT scans performed early in ICI appears predictive for eventual response in patients with advanced melanoma. These findings require validation in larger cohorts.
引用
- Cho SY, Lipson EJ, Im HJ, et al. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med. 2017. PMID: 28360208. doi:10.2967/jnumed.116.188839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。